Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs [3] - The company has a differentiated late-stage clinical pipeline that includes three core product candidates: OCS-01, OCS-05, and OCS-02 [3] Product Pipeline - OCS-01 is an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema [3] - OCS-05 is a neuroprotective candidate in Phase 2 for acute optic neuritis, with potential applications in various neuro-ophthalmic and neurological diseases [3] - OCS-02 is a novel topical anti-TNFα in Phase 2, developed with a genotype-based approach for personalized medicine in dry eye disease [3] Upcoming Events - Oculis management will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 [1] - A corporate update presentation will be available for replay via webcast at 7:00am ET, and a live panel discussion on pivotal-stage assets for retinal disorders will occur from 11:00am to 12:00pm ET [4]